We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 81

Generic Health succeeds in invalidating patent for aripiprazole: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) 2015 FCA 634
  • King & Wood Mallesons
  • Australia
  • July 7 2015

Generic Health is perhaps a step closer to bringing its generic version of the antipsychotic drug aripiprazole to market in Australia after Justice


Otsuka successful in stay application: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd 2015 FCA 848
  • King & Wood Mallesons
  • Australia
  • August 26 2015

Further to our post of 7 July 2015, the proceedings brought by Otsuka and Bristol Myers Squibb (the "exclusive licensee" of Otsuka's patents for


Australian case notes - Odisho v Bonazzi 2014 VSCA 11
  • King & Wood Mallesons
  • Australia
  • May 20 2014

In this case the appellant, a patient who suffered a thromboembolic event following the use of tranexamic acid, claimed that her doctor had


Vision Eye Institute Ltd v Kitchen (no 2) 2015 QSC 66
  • King & Wood Mallesons
  • Australia
  • July 2 2015

In this case, the Queensland Supreme Court awarded a significant amount of damages for contingent loss of income flowing from a breach of contract


Privacy Commissioner’s decision set aside by the Federal Court
  • King & Wood Mallesons
  • Australia
  • March 16 2015

A recent decision by Federal Court of Australia illustrated two things about privacy complaints - or at least those that end up before the courts:


Just genes? Lessons from the Myriad litigation
  • King & Wood Mallesons
  • Australia
  • August 19 2013

Last month the United States Supreme Court ruled that certain naturally occurring DNA sequences (the BRCA1 and BRCA2 genes, mutations in which are


High Court grants special leave to appeal extension of time in pharmaceutical patent case
  • King & Wood Mallesons
  • Australia
  • April 15 2014

Last Friday the High Court of Australia granted Alphapharm special leave to appeal from a decision of the Full Federal Court in Aspen Pharma Pty Ltd


Experimental evidence comply with the rules or risk inadmissibility
  • King & Wood Mallesons
  • Australia
  • March 22 2013

By refusing to allow Generic Health to adduce experimental evidence in a patent case currently being heard in the Federal Court, Justice Jagot has


Australian court decides important gene patenting question isolated genetic material patentable subject matter
  • King & Wood Mallesons
  • Australia
  • February 15 2013

Earlier today, the Federal Court rejected a claim brought by Cancer Voices Australia that isolated genetic material (DNA or RNA) that is naturally


Those drugs cost how much?? Chemist warehouse price list misleading but not for the reasons you might think
  • King & Wood Mallesons
  • Australia
  • October 29 2012

Last Monday the Supreme Court of Queensland held that a price list published by various Chemist Warehouse pharmacies in Cairns, Nerang, Coolangatta and other parts of Queensland was likely to mislead or deceive and therefore contravene clause 18 of the Australian Consumer Law (Competition and Consumer Act 2010 (Cth), schedule 2, section 18